Answers are grounded in this paper and cite their sources.
Clinical review details cyclosporine pharmacology and monitoring in transplant and autoimmune populations, highlighting strategies to manage toxicity.
An immunosuppressive medication called cyclosporine is useful in treating organ rejection following transplantation. Additionally, it shows promise in treating organ rejection in kidney, liver, and heart allogeneic transplants, rheumatoid arthritis, and other autoimmune illnesses where methotrexate has not been effective enough. Also, it is a second-line agent for ALS and graft vs host disease. Other FDA-approved and non-FDA-approved indications are also present. For interprofessional team members treating illnesses where cyclosporine is recommended, this activity explains the drug's mechanism of action, adverse event profile, toxicity, dosage, pharmacodynamics, and monitoring.
No takes yet. Share an insight, caveat, or question.
E. et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: